

Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 376875 Alpha Lipoic 300

ARTG entry for Medicine Listed

Sponsor Herbs of Gold Pty Ltd

Postal Address PO Box 3143, KIRRAWEE, NSW, 2232

Australia

ARTG Start Date 26/10/2021

Product Category Medicine

Status Active

Approval Area Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Alpha Lipoic 300

Product Type Single Medicine Product Effective Date 15/02/2023

Permitted Indications

Antioxidant/Reduce free radicals formed in the body

Maintain/support energy production

Maintain/support blood vessel health

Aid/assist/helps glucose/sugar/carbohydrate metabolism

Helps maintain/support cellular uptake of (state vitamin/mineral/nutrient)

Maintain/support nervous system health

Maintain/support nervous system function

Indication Requirements

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size Poison Schedule

Page 1 of 2

Produced at 16.02.2023 at 04:07:56 AEDT



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration

Visual Identification
Active Ingredients

alpha lipoic acid 300 mg

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate colloidal anhydrous silica

hypromellose

magnesium stearate

microcrystalline cellulose

purified water

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.